Helping ovarian cancer patients cope with their illness
Helping Ovarian Cancer Patients Cope With Their Disease (HOPE) - Phase 2
NA · Fred Hutchinson Cancer Center · NCT06666218
This study tests a series of workshops designed to help women with recurrent ovarian cancer feel more hopeful and improve their quality of life compared to those receiving regular care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Fred Hutchinson Cancer Center (other) |
| Locations | 1 site (Seattle, Washington) |
| Trial ID | NCT06666218 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of the HOPE intervention, which consists of a series of workshops aimed at reducing feelings of hopelessness and helplessness in patients with recurrent ovarian cancer. Participants are randomly assigned to either the HOPE intervention group, which involves three weekly sessions, or a control group receiving usual care. The study assesses the mental health outcomes of participants through surveys and interviews conducted at baseline and follow-up intervals. The goal is to improve the quality of life for patients facing the challenges of recurrent ovarian cancer.
Who should consider this trial
Good fit: Ideal candidates are English-speaking adults aged 18 and older with a current diagnosis of recurrent epithelial ovarian cancer.
Not a fit: Patients with non-invasive gynecologic disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the mental health and quality of life for patients with recurrent ovarian cancer.
How similar studies have performed: Other studies have shown that psychological interventions can improve mental health outcomes in cancer patients, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years of age or older * English speaking * Able to provide informed consent * Current diagnosis of recurrent epithelial ovarian cancer (regardless of the amount of time since the diagnosis, given the poor prognosis of this illness with a median survival time of less than 2 years) Exclusion Criteria: * Patients with non-invasive gynecologic disease (i.e., dysplasia)
Where this trial is running
Seattle, Washington
- Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States (RECRUITING)
Study contacts
- Principal investigator: Megan J. Shen, PhD — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Megan J. Shen, PhD
- Email: mshen2@fredhutch.org
- Phone: 206-667-4172
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Recurrent Ovarian Carcinoma